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Background: We sought to describe modes of failure and associated limb loss after infrainguinal polytetrafluoroethylene
bypass grafting in patients lacking a saphenous venous conduit and to define specific clinical or hemodynamic factors
prognostic for bypass failure.
Methods:We identified 121 patients (mean age, 67 years; 90 men and 31 women) with determinable outcomes (minimum
follow-up, 2 months; mean, 17 months) after 130 prosthetic infrainguinal bypasses between 1997 and 2005. Ischemic
presentation was rest pain in 52%, tissue loss in 34%, and disabling claudication and/or popliteal aneurysm in 14%, with
24% of patients requiring a redo bypass. Distal targets were the above-knee (n  44), distal popliteal (n  27), or
tibial/pedal (n 59) arteries. Sixty-six (77%) of the below-knee (BK) target (distal popliteal or tibial) bypasses had distal
anastomotic adjuncts (vein cuff or patch). Duplex graft surveillance was performed at 1, 4, and 7months after surgery and
twice yearly thereafter, with recording of midgraft velocities and imaging encompassing inflow and outflow vessels.
Arteriography and open/endovascular intervention was performed for stenoses identified by duplex scanning (peak
systolic velocity >300 cm/s; velocity ratio >3.5). An attempt was made to salvage occluded grafts by using catheter-
directed thrombolysis or open techniques. Eighty-six patients (74% of BK bypasses) were placed on chronic warfarin
therapy with a target international normalized ratio range between 2 and 3. Prognostic factors were identified by using
univariate statistics and multivariate logistic regression analysis.
Results: Three-year primary, assisted, and secondary patency rates were 39%, 43%, and 59%, respectively, for all bypasses,
with no difference noted between above-knee and BK grafts (P  .5). At 3 years, freedom from limb loss was 75%, and
patient survival was only 70%, with no adverse effect on survival imparted by amputation. Sixty-nine total adverse events
occurred as a result of thrombotic occlusion (n 51), duplex scan–detected stenosis (n 13), or graft infection (n 5).
Forty-nine percent of all initial graft occlusions eventually led to amputation. Twenty-three grafts (27% of 86 patients)
in patients maintained on chronic warfarin were subtherapeutic at the time of occlusion. Use of a distal anastomotic
adjunct with BK bypasses reduced graft thrombosis (35% with vs 60% without) but did not impart a significant patency
advantage (P  .07). Multivariate analysis revealed low graft flow (midgraft velocity <45 cm/s; odds ratio [OR], 6.1;
95% confidence interval [CI], 1.9-19.2), use of warfarin (OR, 8.4; 95% CI, 2.1-34.5), and therapeutic warfarin (OR,
24.6; 95% CI, 5.7-106) to be independently predictive for bypass patency. Graft patency was maintained in 89% of grafts
remaining therapeutic on warfarin compared with only 55% of subtherapeutic or nonanticoagulated grafts (P < .001).
Low-flow grafts (n 61) occludedmore frequently than higher-flow grafts (46% vs 13%; P< .001). Therapeutic warfarin
augmented the patency of low-flow (P < .001) but not high-flow (P  .15) grafts.
Conclusions: Low graft flow was a more common mode of prosthetic bypass failure than development of duplex
scan–detected stenotic lesions during follow-up. Early duplex scanning may be more important for characterizing
midgraft velocity and related thrombotic potential and selecting patients for chronic anticoagulation. Maintenance of
therapeutic warfarin is paramount in optimizing prosthetic bypass patency and limb preservation. (J Vasc Surg 2007;46:
1160-6.)Acknowledging the superior patency of infrainguinal
saphenous vein bypass grafts (60%-85% at 5 years1), espe-
cially to distal popliteal, tibial, or pedal target vessels,
debate continues regarding the choice of alternative con-
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1160duit when a great saphenous vein is unavailable (ie, has
been previously harvested) or is unusable (diameter 2.5
mm, dilated with varicose changes, or of limited length).
Comparable patency rates of lower limb bypasses per-
formed with arm vein have ranged from 40% to 90% at 3
years2-4 but incur the added time and morbidity of vein
harvest, frequent need for composite or spliced conduit
construction, and a high incidence of early conduit reste-
nosis. Although having the potential advantage of a more
expeditious and less invasive procedure, infrainguinal pros-
thetic bypasses extended to below-knee (BK) targets have
had disappointing patency rates of 12% to 40% at 3 to 5
years.5-7 Numerous adjuncts have been suggested to im-
prove patency and potential limb salvage rates for infrain-
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tion of a venous cuff or patch to the distal anastomotic
region of lower limb PTFE bypasses hasmodestly improved
graft patency rates in numerous series.5,8-10 Despite the
failure to demonstrate efficacy for warfarin anticoagulation
after “routine” infrainguinal bypass performed with a ve-
nous conduit from two randomized trials,11,12 warfarin has
improved patency in other “high-risk” bypass experiences13
and may also possess a role for infrainguinal PTFE by-
passes.12,14,15 Use of duplex ultrasound surveillance may
not augment the patency of infrainguinal PTFE bypasses
because bypass-threatening stenoses develop most com-
monly in the inflow and outflow vessels,16 but graft velocity
may prove prognostic, as we recently found for prosthetic
cross-femoral bypasses.17 We reviewed our experience with
infrainguinal PTFE grafts to specifically gauge limb salvage
potential and the relative effectiveness of distal anastomotic
adjuncts and long-term warfarin anticoagulation and to
determine what role duplex ultrasound surveillance may
have in patency augmentation.
METHODS
Patient cohort. A retrospective review was performed
from our vascular division database identifying 121 patients
(mean age, 67 years; range, 45-90 years; 90 men and 31
women) undergoing 130 PTFE infrainguinal bypasses for
lower limb ischemia. This represents 16% of all infraingui-
nal bypasses performed between 1997 and 2005 at Tampa
General Hospital or James A. Haley Veterans Hospital
(Tampa, Fla). In the absence of adequate or available
ipsilateral or contralateral saphenous vein, single-segment
or spliced arm vein conduits were used preferentially in 14%
of patients during this interval. No patient undergoing
PTFE bypass had a usable saphenous vein. Seventy-eight
patients (64%) did not have an adequate length or caliber
(2.5 mm) of arm vein for bypass construction according
to preoperative ultrasound vein mapping. Cadaveric vein
was not considered a viable option for bypass construction.
PTFE bypasses were placed for rest pain alone in 52% (n
68), ischemic ulceration or gangrene in 34% (n  44),
severe disabling claudication (grade III18) in 10% (n  13),
and popliteal aneurysm with associated occlusive disease in
4% (n 5). Comorbidities included diabetes mellitus in 50
patients (39%), dialysis-dependent renal failure in 7 (6%),
and previous contralateral major amputation in 13 (10%).
Prior or concomitant ipsilateral inflow reconstruction
(open or endovascular) was performed in 26 patients
(20%), and 24 % (n  31) had experienced failure of
previous infrainguinal ipsilateral bypasses. Twelve (9%) in-
frainguinal PTFE bypasses were considered urgent (per-
formed within 24 hours of ischemic presentation).
Perioperative management. All new bypasses were
constructed with 6-mm PTFE conduits originating from
proximal femoral arteries. Distal targets were to above-knee
(AK; n  44) and distal (n  27) popliteal arteries or to
tibial or pedal vessels (n 59) according to preoperative or
intraoperative arteriography. Distal anastomotic adjuncts
were used with 67 (52%) of all bypasses and with 66 (77%)BK grafts (to distal popliteal or tibial targets; Table I).
Distal vein patches (Linton or Taylor) were used in 18
cases, Miller cuffs were used in 30 patients, and composite
PTFE grafts with a short length (15 cm) of vein spliced
into the BK segment were used in 15 cases. Basilic vein was
the most common source for the autologous distal ad-
juncts. Precuffed 6-mm PTFE grafts (Impra Distaflo; Bard
Inc, Murray Hill, NJ) were used in only four patients (one
to an AK popliteal target). Forty-three (98%) of 44 bypasses
to the AK popliteal artery were performed without distal
anastomotic adjuncts.
Perioperative administration of an antiplatelet agent
(aspirin 81 or 325 mg/d or clopidogrel 75 mg/d), dextran
40 (25 mL/h for 24 hours after surgery), and low-molecular-
weight heparin (40-60 mg/d subcutaneously) was rou-
tinely used in the absence of excessive early postoperative
hemorrhage. On the basis of surgeon preference but gen-
erally considered for all BK bypasses lacking major contra-
indications (significant risk of falls or active or recent hem-
orrhage), warfarin anticoagulation was initiated on the first
or second postoperative day with a long-term target inter-
national normalized ratio (INR) of 2 to 3. Warfarin was
used with 86 (66%) of all bypasses and 64 (74%) BK grafts
(Table I). Most patients with AK popliteal bypasses were
continued on warfarin prescribed for other indications
(atrial fibrillation, prosthetic cardiac valves, or a known
hypercoagulable state). Therapeutic low-molecular-weight
heparin (1 mg · kg1 · d1) was used for most bypasses as
a bridge (1-2 weeks) during early warfarin dosing after
hospital discharge. Our division regulated warfarin dosing
(3-6 weeks) until primary care physicians could assume
management in most patients. Regardless of warfarin use,
daily aspirin (81 or 325 mg) was prescribed indefinitely in
all patients. Clopidogrel (75 mg daily) was prescribed in-
definitely with daily aspirin for patients not receiving war-
farin.
Duplex ultrasound surveillance protocol. Intraop-
erative duplex ultrasound assessment was performed in only
41% of patients with spectral velocity recordings obtained
in the inflow and outflow arteries and autologous vein
Table I. Distal anastomotic and anticoagulation adjuncts







Distal anastomosis 1 (2%) 66 (77%)
Vein cuff or patch 0 48
Composite/spliced vein 0 15







AK, Above knee; BK, below knee.segments of the distal anastomosis. Operative revision was
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greater than 250 cm/s within these vessel segments. Color
Doppler flow in the newly placed PTFE graft could not be
visualized during surgery. However, duplex imaging of
the midbypass segment (remote from operative incisions),
recording of midgraft peak velocity (MGV), and measure-
ment of Doppler imaging–derived ankle systolic (ankle-
brachial index) and toe pressures were performed in most
patients before hospital discharge.
Long-term surveillance included clinical assessment for
recurrent limb ischemia, measurement of ankle-brachial
indexes and toe pressures, and color duplex scanning. Graft
surveillance was performed 4 to 6 weeks after surgery, 3
months later, and then at 6-month intervals thereafter.
Color scanning after infrainguinal PTFE bypasses differed
from the techniques used for lower limb vein bypasses19 in
that additional imaging was performed over a longer length
(10-15 cm) of inflow and outflow arteries, and spectral
recording was made from only three nonanastomotic, in-
tragraft sites without contiguous imaging along the entire
bypass in the absence of changes in waveform morphology
between sites. MGV was calculated as the average PSV of
these three proximal, mid, and distal bypass values, and a
low-flow graft was defined as an MGV of 45 cm/s or less.
The threshold criteria recommended for repair of duplex
scan–detected high-grade stenosis included PSV greater
than 300 cm/s and a local velocity ratio greater than 3.5.19
Arteriography and potential intervention were also consid-
ered for a decrease in the ankle-brachial index by 0.15 or
toe pressure by 20 mm Hg or a decrease in the MGV by
greater than 20 cm/s associated with an adverse change in
spectral waveforms in the absence of identification of a
stenosis. Development of a moderate-grade stenosis (PSV
225 cm/s and a velocity ratio 2.0) prompted repeat
duplex imaging at 3-month intervals. Duplex criteria for
reintervention to correct recurrent repair-site abnormalities
were identical to those used for the initial procedure.
Secondary interventions. Thrombotic occlusions of
bypasses confirmed by duplex scanning were treated imme-
diately with unfractionated heparin infusion and consid-
ered for salvage interventions depending on the associated
limb ischemia severity. Catheter-directed thrombolysis was
considered for moderate degrees of ischemia (some distal
neurologic sensory loss), especially when arteries beyond
the occluded graft contained significant thrombus. Open
surgical thrombectomy was emergently performed for
more severe ischemia (any distal motor loss) with liberal use
of intraoperative thrombolytic agents in the outflow ves-
sels. After adequate recanalization of the occluded bypass,
any underlying arteriography-detected stenoses greater
than 50% were treated by either endovascular or open
techniques (endarterectomy, patch angioplasty, interposi-
tion graft segment replacement, or jump bypass to a new
distal target artery). Anatomic criteria for transluminal bal-
loon angioplasty of proximal or distal anastomotic graft or
outflow artery stenoses revealed after recanalization of oc-
cluded bypasses or duplex scan–detected stenoses occur-
ring in patent grafts included a stenosis length of less than 2cm in a bypass more than 3 months after original construc-
tion. Iliac inflow stenoses of any length were generally
treated with primary stenting. Repeat duplex evaluation
was performed within 1 to 4 days after secondary interven-
tions to confirm adequate repair at stenotic sites (widely
patent lumen by color Doppler imaging, PSV200 cm/s,
and a velocity ratio 2). Replacement with a new PTFE
bypass graft was performed after inadequate open and
endovascular recanalization of failed grafts. Wide local ex-
cision and ligation of thrombosed grafts was performed at
anastomotic sites to reduce the risk of new prosthetic
infection. Thrombosed or patent PTFE grafts presenting
with perigraft fluid collections and local signs of infection
more than 3 months after construction were treated in
staged fashion, as previously described.20 Local sterilization
(negative cultures and no residual purulent fluid) of pros-
thetic graft infections after repeated debridement proce-
dures allowed in situ replacement with rifampin-treated
PTFE. Incompletely eradicated infections or infections
associated with virulent bacterial strains (gram-negative
strains) were treated by in situ or extra-anatomic replace-
ment with arm vein or other autologous vessel (endarter-
ectomized superior femoral artery).
Data analysis. Adverse patient outcomes, including
death, bypass thrombosis, graft revision, graft infection,
and amputation, were recorded throughout follow-up. All
patients had determinable follow-up beyond 2 months that
ranged to 82 months and averaged 17 months. Patients
with perioperative deaths (60 days) were excluded to
focus on longer-term modes of graft failure. Primary, as-
sisted primary, and secondary patency; limb salvage; and
patient survival were calculated by using Kaplan-Meier
techniques as recommended by the reporting standards
committee of the Society for Vascular Surgery.18 Compar-
isons between patency curves for different treatment
groups were assessed by a log-rank statistic. Potential prog-
nostic factors associated with graft failure (thrombotic oc-
clusion) were evaluated for categorical variables by using
contingency table (2 or Fisher exact tests) analyses and
confirmed with a multivariate stepwise logistic regression
analysis. This retrospective study was approved by our
institutional review board.
RESULTS
Late outcomes. An average of 4.2 graft surveillance
studies were performed after hospital discharge for each
patient. Duplex studies identified 13 (10%) high-grade
stenoses in patent bypasses that occurred in the inflow/
proximal anastomotic graft segment in 5 cases and in the
outflow/distal anastomotic graft segment in 8 cases
(Table II). No stenosis was found within the body of the
prosthetic grafts. Stenoses were treated by endovascular
techniques in eight cases (transluminal balloon angioplasty
of four proximal anastomotic graft and distal anastomotic
graft stenoses each) and open revisions in five bypasses
(three patch angioplasties and two segmental distal graft/
distal anastomotic graft replacements). Low graft flow
(MGV 45 cm/s) was detected in just less than half of all
nJOURNAL OF VASCULAR SURGERY
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during predischarge or at the initial 1-month imaging and
persisted during follow-up. Eleven of 13 stenotic grafts
developed low graft flow during follow-up and before
secondary intervention. Bypasses to an AK popliteal target
exhibited a larger proportion of high-flow characteristics
(61%; 27/44) than low-flow characteristics (39%). Low
flow was found in half (51%; 44/86) of BK bypasses.
Despite surveillance, 51 (39%) bypasses occluded dur-
ing follow-up (Table II). There were 30 single thrombotic
events and 21 multiple (recurrent) thromboses. Secondary
interventions were performed for 32 (63%) occlusions.
Salvage of the existing bypass was possible in 18 cases, and
14 necessitated new bypass construction. Segmental PTFE
graft infection occurred in five patients (4%), with four
bypasses salvaged by an interposition rifampin-treated
PTFE conduit (n  2) or autologous (arm vein or endar-
terectomized superior femoral artery) interposition (n  2).
One infected (and thrombosed) graft necessitated amputa-
tion, and the other 25 major amputations were performed
after bypass occlusions. Graft occlusion eventually led to
amputation in 49% (25/51) of afflicted patients. A single
patient presenting initially with claudication (1/18; 6%)
required amputation after multiple secondary interventions
for multilevel disease and recurrent bypass failure.
The mean interval between bypass construction and an
Fig 1. Kaplan-Meier estimates of primary, assisted, and secondary
patency for 130 infrainguinal polytetrafluoroethylene bypasses ac-
cording to duplex surveillance. The number of at-risk bypasses is
shown at 6 months and annual follow-up intervals; standard error
(SE) remained less than 10% until 4 years. Significant patency
augmentation (log rank; P  .025) was accomplished through
secondary interventions on stenotic and occluded bypasses.
Table II. Outcomes of all threatened or failed prosthetic
Occlusions (n  51)
Secondary intervention (n  32)
Open thrombectomy with revision 8 Translu
Thrombolysis with transluminal balloon angioplasty 8 Open r
Thrombolysis with open revision 2
New replacement graft 14
Amputation, n  25 (49%)initial secondary intervention was 9.5 12.5 months. Theaverage time between initial and recurrent interventions
was 8.9  10.5 months. The overall 3-year primary, as-
sisted, and secondary graft patency rates were 39%, 43%,
and 59%, respectively (Fig 1). There was no difference (P 
.5) in 3-year patency rates for AK popliteal (37% primary,
40% assisted, and 67% secondary) and BK (38%, 44%, and
55%) bypasses. The overall limb salvage rate for the series
was 83% at 1 year and 75% at 3 years. Twenty patients died
during follow-up, with two deaths attributed to treatment
complications for recurrent limb ischemia. Survival was
only 70% at 3 years and was not adversely affected by the
need for eventual amputation (71%with amputation vs 70%
without; P  .4).
Correlative analysis. Potential univariate correlates of
bypass occlusion are detailed in Table III. Claudication or
popliteal aneurysm at presentation and therapeutic warfarin
during follow-up were associated with continued graft pa-
tency, whereas low graft flow (MGV 45 cm/s) was asso-
sses
enosis (n  13) Infection (n  5)
 13 n  4
l balloon angioplasty 8 Rifampin-soaked replacement graft 2
n 5 Autologous conduit graft 2
 0 (0%) n  1 (20%)
Table III. Univariate (contingency table) analysis of








Sex (female) 11 (22%) 22 (28%) .39
Smoking 25 (49%) 40 (51%) .86
HTN 33 (65%) 52 (66%) .90
Hyperlipidemia 18 (35%) 35 (44%) .31
Diabetes mellitus 19 (37%) 31 (39%) .82
CAD (angina, MI) 21 (41%) 38 (48%) .44
COPD 6 (12%) 12 (15%) .58
Contralateral amputation 3 (6%) 10 (13%) .21
Prior ipsilateral bypass 13 (26%) 18 (23%) .72
Prior/concomitant inflow
procedure 12 (24%) 14 (18%) .42
Claudication/pop aneurysm 3 (6%) 15 (19%) .04*
Rest pain 32 (63%) 36 (46%) .06
Tissue loss (ulcer, gangrene) 16 (31%) 28 (35%) .60
BK target (distal pop, tibial) 35 (69%) 51 (65%) .89
Distal anastomotic adjunct 23 (45%) 44 (56%) .24
Distaflo graft 3 (6%) 1 (1%) .14
Warfarin 36 (71%) 50 (63%) .39
Therapeutic warfarin 7 (14%) 56 (71%) .001*
Low-flow graft (MGV
45 cm/s) 28 (57%) 33 (41%) .03*
PTFE, Polytetrafluoroethylene; HTN, hypertension; CAD, coronary artery
disease; MI, myocardial infarction; COPD, chronic obstructive pulmonary
disease; BK, below knee; MGV, midgraft peak velocity; pop, popliteal.




evisiociated with thrombosis. Use of a distal anastomotic adjunct
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included. For BK bypasses, there was a stronger trend
toward reduced graft thrombosis (35% [23/66] with distal
adjunct vs 60% [12/20] without; P  .07). Multivariate
logistic regression analysis revealed low graft flow (odds ratio
[OR], 6.1; 95% confidence interval [CI], 1.9-19.2;P .002),
use of warfarin (OR, 8.4; 95% CI, 2.1-34.5; P .003), and
therapeutic warfarin (OR, 24.6; 95% CI, 5.7-106; P 
.001) to be independently predictive for bypass patency.
Continued patency was more frequent for higher-flow
grafts (87%; 60/69) than low-flow (MGV 45 cm/s)
bypasses (54%; 33/61; P .01). Subtherapeutic anticoag-
ulation (INR2) was found at the time of bypass occlusion
in 23 (27%) of the 86 patients treated with chronic warfa-
rin. Graft patency was maintained in 89% (56/63) of
patients with therapeutic warfarin (INR 2) dosing, com-
pared with only 55% (37/67) of subtherapeutic or nonan-
ticoagulated grafts (P  .01). Forty-five (52%) of the 86
patients placed on long-term warfarin possessed low-flow
grafts, whereas 41 patients exhibited MGV greater than 45
cm/s. Alternatively, 45 (74%) of the 61 low-flow grafts
were in patients taking warfarin, whereas 41 (59%) of 69
patients with high-flow bypasses received warfarin. Eighty-
five percent (23/27) of low-flow grafts in patients receiving
therapeutic warfarin remained patent, compared with only
29% (10/34) of grafts in patients receiving subtherapeutic
doses or not receiving anticoagulation and having an MGV
of 45 cm/s or less (P  .0001; Fig 2). The beneficial effect
of therapeutic warfarin on the patency of low-flow grafts
was present for both AK popliteal (100% [6/6] vs 36%
[4/11] subtherapeutic/no anticoagulation; P  .03) and
BK (81% [17/21] vs 26% [6/23] subtherapeutic/no anti-
coagulation; P .0004) bypasses. By contrast, therapeutic
Fig 2. Thrombotic outcome of low-flow (midgraft peak velocity
45 cm/s) infrainguinal bypasses (n  61). A significant patency
benefit was seen for therapeutic warfarin over subtherapeutic or no
anticoagulation (sub/no) for both above-knee popliteal (P  .03)
and below-knee target grafts (P  .0004).warfarin was not protective for either high-flow BK (P .38) or AK (P  .27) bypasses as a result of the overall low
incidence (9/69) of high-flow graft occlusions (Fig 3).
DISCUSSION
This study sought to define failure modes related to
infrainguinal PTFE grafts constructed principally for limb
threatening ischemia and to define potential prognostic
factors. The addition of an autologous vein patch, cuff, or
short interposition segment to the distal anastomotic re-
gion was performed in most PTFE bypasses to BK targets
(distal popliteal or tibial; 77%) but did not improve patency
for the entire study cohort. Despite a trend toward reduced
bypass occlusion when only BK grafts were studied, distal
anastomotic adjuncts had less effect on patency than graft
flow rate or warfarin. Although the benefit of adding a
distal anastomotic adjunct to BK target PTFE bypasses has
been suggested in several studies,5,9,10,21 definitive evi-
dence has been shown in only one randomized prospective
trial.8
We observed that low graft flow, defined by an MGV
less than 45 cm/s, was present in 47% of PTFE bypasses
and was associated with twice as many bypass occlusions as
development of graft-threatening stenotic lesions detected
by duplex surveillance (29 vs 13). Low graft flow was most
common in BK target PTFE conduits (51%) and possessed
a sixfold higher risk of occlusion than high flow (MGV45
cm/s) according to multivariate analysis. Early in-hospital
duplex scanning after bypass construction can easily be
performed through the typically unoperated midthigh re-
gion to characterize the graft flow regimen and aid selec-
tion of patients for chronic anticoagulation because thera-
peutic warfarin improved the patency of low-flow PTFE
grafts to both AK popliteal and BK targets. Because of the
compromised longevity of infrainguinal PTFE bypasses, we
Fig 3. Thrombotic outcome of high-flow (midgraft peak velocity
45 cm/s) bypasses (n 69). No additional benefit of therapeutic
warfarin was found for infrainguinal bypasses (P  .15), including
above-knee (P .27) and below-knee (P .38) target subgroups.
Sub/no, Subtherapeutic or no anticoagulation.recommend that duplex surveillance be performed at pre-
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imaging of inflow and outflow arteries 10 to 15 cm beyond
anastomoses, serial duplex scanning may capture the ste-
notic development responsible for roughly one fifth of all
graft failures. Thirteen (19%) of 69 threatened or failed
bypasses and 10% of all bypasses in the series had stenoses
detected by duplex surveillance. The most common loca-
tion of stenosis found by surveillance was at the distal
anastomotic site, and it was successfully remediated by both
endovascular and open techniques. Accordingly, secondary
interventions performed for duplex scan–detected stenoses
increased assisted patency by 5% to 10% over the primary
patency distribution for PTFE grafts. Because of the high
incidence of PTFE bypass failure and risk of limb loss, we
recommend ongoing duplex surveillance to provide this
incremental improvement in graft patency.
Maintenance of therapeutic anticoagulation (INR 2)
during chronic administration of warfarin had a profound
influence on PTFE bypass patency. Low-dose aspirin (81
mg) was routinely prescribed with warfarin in our series and
may have potentiated its protective effect. Therapeutic
warfarin markedly reduced the risk of thrombosis of low-
flow (MGV 45 cm/s) bypasses to both AK and BK
targets but not of high-flow grafts because of their lower
overall risk of occlusion (13%). “Routine” use of warfarin
has not improved the patency of infrainguinal bypass in
several prospective trials.11,12 However, warfarin pre-
scribed for “high-risk” graft indications, including redo,
composite saphenous or alternative (arm or small saphe-
nous) vein bypasses, and compromised tibiotarsal outflow,
has augmented patency in a randomized prospective trial.13
Other studies have demonstrated a modest patency benefit
of warfarin for infrainguinal prosthetic grafts,12,14 thus
leading to a consensus statement supporting its use with
high-risk and prosthetic infrageniculate bypasses.15 Jackson
et al22 showed a reduction in the severity of limb ischemia
encountered when infrainguinal PTFE grafts occlude in
patients maintained on chronic warfarin and aspirin com-
pared with those receiving aspirin alone. This observation
was potentially due to less extensive thrombus propagation
into adjacent native vessels and collateral pathways in pa-
tients maintained onmore aggressive anticoagulation (war-
farin). In the absence of major contraindications, we would
recommend long-term warfarin therapy for PTFE bypasses
constructed to distal popliteal or tibial (BK) targets and all
low-flow grafts, including those to the AK popliteal artery,
on the basis of our results. The larger management problem
lies in how to reduce the incidence (and deleterious effect)
of subtherapeutic warfarin dosing. More than one quarter
of our patients were subtherapeutic (INR2.0) at the time
of bypass occlusion. Even a higher rate (40%) of noncom-
pliance and inadequate warfarin dosing was observed in a
prospective randomized study evaluating warfarin for pe-
ripheral arterial bypass constructions necessitating patient
consent and acceptance of an assigned treatment regi-
men.12 Optimizing patient compliance and safety during
warfarin administration requires INR blood draws and
dosage adjustments best organized through dedicated“Coumadin clinics,” but a relative paucity of such centers
exists in most hospital, clinic, and group practice systems.
Reliance on primary care physicians to coordinate warfarin
management may not be the best option for assuring
compliance, and ultimately, the responsibility for managing
warfarin therapy may lie with the operating surgeon. As we
promote complete vascular care for our patients, assump-
tion of warfarin management should become one of our
efforts in practicing vascular medicine.
Finally, the most important measure of bypass con-
struction value in treating critical ischemia is limb preserva-
tion.Midterm amputation rates more than 50% observed in
a large meta-analysis of infrainguinal prosthetic bypasses
performed for limb threat5 has led to questioning offering
such bypasses when no autologous venous conduit exists
and primary amputation may be indicated. Limb salvage
was 75% at 3 years in our series despite overall graft patency
rates that were not appreciably better than those in other
reported prosthetic series.5-10,14 PTFE bypasses were a last
option for most of our patients, although a small fraction
presented without limb threat (grade III severe claudica-
tion). Fairly aggressive efforts were directed at salvage of
existing grafts or construction of new bypasses after first-
time PTFE bypass occlusions; amputation was thus avoided
after initial graft failure events in two thirds of cases. Sec-
ondary interventions for occlusive lesions were durable and
added an average of nine additional months of bypass
patency. Treatments of prosthetic graft infections, in addi-
tion to interventions for occlusions and stenoses, were all
effective in remediating bypass failures. By comparison,
only 70% of our patients were alive after 3 years, with 90%
succumbing to comorbidities unrelated to management of
their limb ischemia. Limb preservation after infrainguinal
PTFE bypass is attainable in a significant number of high
medical risk patients with limited longevity and should be
offered.
CONCLUSIONS
Specific modes of graft failure were detailed from a
series of patients, most with limb-threatening ischemia,
undergoing infrainguinal PTFE bypasses. Low graft flow
threatened graft patency more frequently than develop-
ment of duplex scan–detected stenoses. Therapeutic war-
farin dosing significantly reduced the incidence of bypass
occlusion, especially for low-flow grafts. Duplex scanning
seemsmost important for early in-hospital determination of
MGV and for selection of patients who may benefit from
long-term warfarin administration.
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